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Accepted 12 January 2013AbstractObjectives: To assess the extent of immortal time bias in estimating the clinical effectiveness of implantable cardioverter-defibrillators
(ICDs) and the impact of methods of handling immortal time bias.
Study Design and Setting: Retrospective population-based cohort study of patients with heart failure in a national registry linked to
Medicare claims (2003e2008). We compared three methods of handling immortal time bias, namely the ManteleByar (or time-dependent
exposure assignment), the landmark, and the exclusion methods.
Results: Of the 5,226 study patients, 1,274 (24.4%) received ICD therapy. Total person-years in the ManteleByar method were 2,639,
or 490 more than that in the exclusion method, reflecting potential immortal time in the study. The exclusion method yielded a hazard ratio
of 0.71 (95% confidence interval [CI]: 0.63e0.80), which was 16% lower than the ManteleByar method (0.84; 95% CI: 0.75e0.95). The
120-day landmark method yielded similar results to those produced by the ManteleByar method (0.82; 95% CI: 0.72e0.95).
Conclusions: Immortal time bias was detected in the ICD clinical effectiveness study, which might have led to substantial bias over-
estimating the treatment effect if handled by exclusion. When an appropriate landmark was selected, that method yielded similar hazard
ratios to those obtained by the ManteleByar method, supporting the validity of the landmark method.  2013 Elsevier Inc. All rights
reserved.
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‘‘Immortal time’’ is the follow-up period during which,
in some studies, the outcomes of interest cannot occur
[1,2]. For example, in observational studies of treatment ef-
fectiveness, immortal time can arise if the definition of
treatment is made over time, that is, patients may receive
delayed treatment within a certain period after cohort entry.
The time between cohort entry and the date of treatment is
immortal, meaning that these patients must survive until
they receive the treatment. Either misclassifying this im-
mortal time or omitting it from the analysis can bias theConflict of interest: The authors have no conflicts of interest related to
the content of this article.
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http://dx.doi.org/10.1016/j.jclinepi.2013.01.014estimates in favor of the treatment being studied [3e6]
and therefore affect the study’s conclusions.
At least three approaches have been proposed to correct
bias from immortal time. Mantel and Byar [7] first pro-
posed that person-time should accrue to the various expo-
sure states that patients occupy during treatment. It is
also called time-dependent exposure assignment and is con-
sidered a gold standard method for handling immortal
person-time bias. In the 1980s, Anderson et al. [8] proposed
the landmark method for handling immortal time bias. Spe-
cifically, a fixed time after the initiation of therapy is se-
lected as the landmark. Patients on study at the landmark
time are classified into two exposure categories according
to the patient’s exposure status at the landmark, and are
then followed from the landmark regardless of subsequent
shifts in exposure status. Patients who die before the land-
mark time are excluded from the analysis. This approach
effectively removes immortal time bias. However, the
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 We compared ManteleByar, landmark, and exclu-
sion methods of handling immortal time bias in
a study of the clinical effectiveness of a medical
device. We examined how the choice of time scale
affects these methods.
 Immortal time can bias the results and thus the in-
ference when it is handled inappropriately.
 Immortal time bias can be corrected by using ap-
propriate design and statistical analyses, such as
the ManteleByar method. Landmark is also a valid
method when an appropriate landmark is selected.
 The exclusion method is biased in favor of the
treatment group and should be avoided.
results may differ depending on the choice of the landmark.
Exclusion of patients who die before the landmark time
may lead to lower statistical power. A third and more con-
troversial option is the exclusion method [1,2,8,9], in which
immortal time is excluded from the analysis, patients who
initiate therapy begin follow-up at initiation, and patients
who never initiate therapy begin follow-up at cohort entry.
Despite the recognition of available methods for handling
immortal time bias, immortal time has frequently been mis-
handled in recently published observational studies of drug
effects [5].
Observational comparative effectiveness studies often
use time to event as the outcome [3,4,6,10e16]. The choice
of time origin and scale in these studies (hereafter time
scale) can affect the composition of the risk sets and there-
fore the estimates of hazard ratios from Cox proportional
hazards models [17,18]. Although time on study is the most
commonly used time scale, one previous study indicated
that age may be the appropriate time scale [17]. Time on
disease may also be appropriate because it is a predictor
of outcomes and because some interventions, such as med-
ical devices, can be used at different disease stages. The
choice of time scale in study design also affects the validity
of the method selected for handling immortal time in deter-
mining the underlying hazard function [2,8].
Little is known about the impact of various methods of
handling immortal time bias and how the validity of these
methods is affected by the choice of time scale in the
context of comparative effectiveness studies of medical de-
vices. Device therapies involve invasive, costly, and com-
plicated procedures, and eligible patients may not receive
them until their conditions become severe and/or other ther-
apies fail. Therefore, assessing the effectiveness of a device
therapy is subject to immortal time bias. A typical example
is the implantable cardioverter-defibrillator (ICD), which is
indicated for patients with heart failure (HF) to preventsudden cardiac death and has been shown to be efficacious
in clinical trials [19,20]. We used data from a previous
study of the clinical effectiveness of ICDs among Medicare
beneficiaries with HF [11] to evaluate the extent of immor-
tal time bias in comparative effectiveness studies of devices
and to assess the impact of methods of handling immortal
time bias and time scale. In this example, we hypothesized
that the most appropriate method will yield hazard ratios
similar to or higher than those from the trials, as the effec-
tiveness of ICDs was expected to be attenuated in Medicare
beneficiaries, who are older and have greater comorbidity
than trial participants and are therefore more likely to die
from causes other than sudden arrhythmic death.2. Methods
2.1. Study population
The study data were from the American Heart Associa-
tion’s Get With the Guidelines-Heart Failure (GWTG-HF)
registry and Medicare inpatient claims from the Centers
for Medicare & Medicaid Services (CMS). Details of the
design and objectives of the GWTG-HF registry have been
described previously [21]. We linked the GWTG-HF regis-
try to Medicare inpatient claims using the method described
by Hammill et al. [22]. We used the same inclusion criteria
as a previous study of the clinical effectiveness of ICDs
[11]. The final data set included 5,226 eligible patients
who were discharged home alive between January 1,
2003 and December 31, 2008 from 193 hospitals. The co-
hort entry was defined as the date of discharge from the in-
dex hospitalization, which was not necessarily the patient’s
first hospitalization for HF.
2.2. Measures
The outcome of interest was all-cause mortality during
the 3 years of follow-up after the index hospitalization for
HF. Dates of death were obtained from the CMS enrollment
files. The treatment of interest was ICD therapy during the
index hospitalization or during the 3 years of follow-up. We
identified ICD procedures by searching for ICD-9-CM pro-
cedure codes 3794 and 0051 in the Medicare inpatient
claims or as recorded in the registry. For each of the three
methods of handling immortal time bias, we defined ICD
status as follows (Fig. 1).
2.2.1. ManteleByar method
Patients were followed from the time of cohort entry. For
patients who received ICD therapy, the time between cohort
entry and the ICD implantation date was immortal (which
we classified as non-ICD use), and the subsequent follow-
up time was classified as the ICD follow-up period. We
classified all other patients as non-ICD users. We used
the counting process style of input, which allows multiple
records per patient.
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Fig. 1. Definition of ICD use for each method of handling immortal time bias. ICD, implantable cardioverter defibrillator; HF, heart failure.
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We selected 60 and 120 days after cohort entry as alter-
native landmark times. We classified patients as ICD users
if they received ICD therapy before the landmark time and
as non-ICD users otherwise, regardless of subsequent
changes in ICD status. All patients were followed up from
the landmark time instead of the index date. Patients who
died or for whom data were censored before the landmark
were excluded from the analysis.2.2.3. Exclusion method
For patients who received ICD therapy, follow-up began
on the date of ICD implantation and the immortal time be-
fore the implantation was excluded from the analysis. Forpatients who did not receive an ICD, follow-up began on
the date of cohort entry.
We considered the following time scales, namely the
time of cohort entry (i.e., time on study) and the time of
the first HF hospitalization (a surrogate for time on disease
or disease duration) ascertained from Medicare claims in
the 3 years preceding the cohort entry, and time of birth
(i.e., age).
2.3. Statistical analysis
We describe the patient characteristics by ICD status for
the overall study population and for each analysis cohort
derived from the three methods of handling immortal time
bias. We present frequencies with percentages for
S141X. Mi et al. / Journal of Clinical Epidemiology 66 (2013) S138eS144categorical variables and means with standard deviations
for continuous variables. We compared variables between
treatment groups using c2 tests for categorical variables
and Wilcoxon rank sum tests for continuous variables.
We compared person-years and mortality rates between
the ICD group and the non-ICD group. We used Cox pro-
portional hazards models to estimate the effect of ICD ther-
apy on 3-year mortality. We compared three methods of
handling immortal time bias and three time scales. To con-
trol for confounding, we used propensity scores (PSs) esti-
mated using the high-dimensional PS (hd-PS) algorithm
[23], which is an automated technique that empirically
identifies a large number of potential confounders or prox-
ies for confounders in multiple longitudinal data sets. We
estimated PSs separately for each immortal time bias
method because both the sample size and the number of
treated patients differed by method. We used inpatient diag-
nosis and procedure codes 3 years preceding the initiation
date of the ICD therapy for the ICD group, and 3 years pre-
ceding cohort entry for the non-ICD group. Patient demo-
graphic characteristics were measured at the time of the
ICD procedure for the ICD group and at the time of cohort
entry for the non-ICD group. We fitted the following Cox
proportional hazard models for each combination of the
three methods of handling immortal time bias and three
time scales, namely a model weighted by the inverse prob-
ability of treatment [24], a model stratified on the quintiles
of the hd-PS, and a regression adjusted for the hd-PS. We
used robust standard errors to take into account the correla-
tion of data within hospitals. We also calculated the ad-
justed risk difference in the Cox regression model [25].
All analyses were performed using SAS software version
9.1 (SAS Institute, Inc., Cary, NC).3. Results
Of the 5,226 eligible patients, 650 (12.4%) received ICD
therapy during the index hospitalization. Table 1 shows the
baseline characteristics of the study population by ICD sta-
tus at cohort entry. The ICD users were more likely to be
younger (75.4 vs. 76.5 years), men (75.2% vs. 58.6%),
and white (82.6% vs. 78.6%), to have ischemic HF
(77.5% vs. 72.9%), to receive HF medications, and to have
less comorbidity. An additional 624 (12%) patients re-
ceived ICD therapy after the cohort entry. We created three
analysis cohorts based on the methods of handling immor-
tal time bias. From the Medicare claims, we obtained pa-
tient characteristics at cohort entry for non-ICD users and
at treatment initiation for ICD users (Tables 1e3 in
Appendix at www.jclinepi.com).
For the ManteleByar method, there were 2,639 total
person-years in the ICD group, 490 more than for the exclu-
sion method (Table 2). The difference reflects the amount
of immortal time in the ICD group and suggests the poten-
tial impact of mishandling immortal time in the study.Compared with the non-ICD group, the ICD group had
lower mortality. Compared with the non-ICD group, the ex-
pected number of patients with a prevented event was 6, 8,
6, and 11 among 100 patients who received an ICD for
ManteleByar, the 60-day landmark, the 120-day landmark,
and exclusion methods, respectively.
The c-statistic for the hd-PS models was 0.77. As ex-
pected, there were considerable overlaps of the hd-PS for
the ICD and non-ICD users (Fig. 1 in Appendix at www.
jclinepi.com). We found extreme inverse probability
weighting, which we trimmed in all analyses (Fig. 2 in
Appendix at www.jclinepi.com). The hazard ratios for
ICD effectiveness ranged from 0.66 (95% confidence inter-
val [CI]: 0.58e0.77) to 0.89 (95% CI: 0.78e1.01)
(Table 3). When we used time on study as the time scale
and the PS as a covariate in the outcome model to control
for confounding, the ManteleByar method yielded the
highest hazard ratio (0.84; 95% CI: 0.75e0.95), followed
by the 120-day landmark method (0.82; 95% CI:
0.72e0.95), and the 60-day landmark method (0.78; 95%
CI: 0.68e0.89). The exclusion method yielded the smallest
hazard ratio (0.71; 95% CI: 0.63e0.80). The exclusion
method yielded a hazard ratio approximately 16% lower
than that of the ManteleByar method. Three time scales
yielded similar hazard ratios for the estimates from the
landmark and exclusion methods. In the ManteleByar
analysis, estimates from different time scales varied; the es-
timates using time on study as the time scale were closer to
the null than estimates from the other time scales (hazard
ratio, 0.84; 95% CI: 0.75e0.95).4. Discussion
We compared ManteleByar, landmark, and exclusion
methods of handling immortal time bias and chose different
time scales with which to measure the impact of immortal
time bias and the effectiveness of different approaches.
In a data set from a previous study assessing the clinical
effectiveness of ICDs among Medicare beneficiaries, mis-
handling immortal time bias by the exclusion method re-
sulted in up to 16% bias compared with the gold standard
ManteleByar method. The landmark method tended to pro-
vide appropriate control for immortal time bias when
a proper landmark time was selected.
Large randomized clinical trials have shown that ICDs
provide survival benefits in patients with reduced left
ventricular ejection fraction with HF or after myocardial in-
farction. The Multicenter Automatic Defibrillator Implanta-
tion Trial II reported a hazard ratio of 0.69 (95% CI:
0.51e0.93) [20], and the Sudden Cardiac Death in Heart
Failure Trial (SCD-HeFT) reported a hazard ratio of 0.77
(95% CI: 0.62e0.96) [19]. However, compared with car-
diovascular clinical trial participants, Medicare beneficia-
ries are more likely to be older and women [26]. Older
patients are more likely to have more comorbid conditions
Table 1. Baseline characteristics of the study population at cohort entry
Characteristicsa No ICD (n[ 4,576) ICD (n[ 650) P-value
Age, mean (SD), yr 76.5 (4.7) 75.4 (4.5) !0.001
Male, n (%) 2,681 (58.6) 489 (75.2) !0.001
Race, n (%)
Black 724 (15.8) 61 (9.4) !0.001
White 3,598 (78.6) 537 (82.6)
Other/unknown 254 (5.6) 52 (8.0)
Hispanic ethnicity, n (%) 192 (4.2) 32 (4.9) 0.39
Time with heart failure, mean (SD), yr 0.81 (1.06) 0.65 (0.98) !0.001
Comorbid conditions, n (%)
Anemia 695 (15.2) 59 (9.1) !0.001
Atrial arrhythmia 1,520 (33.2) 227 (34.9) 0.39
Chronic obstructive pulmonary disease 1,268 (27.7) 161 (24.8) 0.12
Chronic renal insufficiency 936 (20.5) 98 (15.1) 0.001
Depression 315 (6.9) 38 (5.8) 0.32
Diabetes mellitus 1,905 (41.6) 247 (38.0) 0.08
Hyperlipidemia 1,936 (42.3) 312 (48.0) 0.006
Ischemic etiology of heart failure 3,335 (72.9) 504 (77.5) 0.01
Peripheral vascular disease 740 (16.2) 87 (13.4) 0.07
Prior heart failure hospitalization 2,787 (60.9) 349 (53.7) !0.001
Prior stroke or transient ischemic
attack
698 (15.3) 79 (12.2) 0.04
Smoking in past year 576 (12.6) 77 (11.8) 0.59
Laboratory tests, mean (SD)
Ejection fraction, % 25.4 (7.0) 23.6 (6.4) !0.001
Hemoglobin, g/dL 12.3 (1.9) 12.8 (1.9) !0.001
Serum creatinine, mg/dL 1.7 (0.9) 1.5 (0.7) !0.001
Serum sodium, mEq/L 138 (4.4) 138 (4.0) 0.24
Systolic blood pressure, mmHg 120 (19.9) 118 (18.9) 0.009
Medications at discharge, n (%)
ACE inhibitor or ARB 3,285 (71.8) 502 (77.2) 0.004
Aldosterone antagonist 943 (20.6) 162 (24.9) 0.01
Antiplatelet agent 2,735 (59.8) 401 (61.7) 0.35
b-blocker 3,658 (79.9) 559 (86.0) !0.001
Calcium channel blocker 306 (6.7) 38 (5.8) 0.42
Digoxin 1,509 (33.0) 260 (40.0) !0.001
Diuretic 2,983 (65.2) 371 (57.1) !0.001
Hydralazine 109 (2.4) 6 (0.9) 0.02
Lipid-lowering agent 2,267 (49.5) 382 (58.8) !0.001
In-hospital procedures, n (%)
Coronary angiography 589 (12.9) 153 (23.5) !0.001
Coronary artery bypass graft surgery 54 (1.2) 6 (0.9) 0.56
Mechanical ventilation 74 (1.6) 11 (1.7) 0.89
Percutaneous coronary intervention 114 (2.5) 22 (3.4) 0.18
Length of stay, mean (SD), d 5.3 (4.1) 6.9 (5.8) !0.001
Length of stay 6 d, n (%) 1619 (35.4) 346 (53.2) !0.001
Abbreviations: ICD, implantable cardioverter defibrillator; SD, standard deviation; ACE, angiotensin-converting enzyme; ARB, angiotensin re-
ceptor blocker.
a All variables are from the Get With the Guidelines-Heart Failure registry.
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results from clinical trials may not directly apply to the
Medicare population [28], and we expected a higher hazard
ratio (O0.70) compared with that from the trials. Results
from the ManteleByar method were the closest to what
we expected.
The results of the landmark analyses varied depending on
the choice of the landmark time. Hazard ratios in the 120-
day landmark analysis were close to those from the Mante-
leByar method. Thus, although the 120-day landmark
seems to be an appropriate approach, there is a tradeoff be-
tween choosing shorter vs. longer landmark times. Whena longer landmark time was used, the number of patients
excluded from the analysis for death or being censored be-
fore the selected landmark time increases. This could affect
the statistical power of the analysis and the generalizability
of the results. It is not surprising that CIs are slightly wider
than those in ManteleByar analysis. Also, when large im-
mediate effects (benefit or adverse effects) from the treat-
ment were expected, estimates from the landmark method
will provide an incomplete picture of the effectiveness of
the treatment. Nonetheless, SCD-HeFT showed that the
benefit of ICD therapy was only observed 1.5 years after
implantation (i.e., delayed effect) [19]. Therefore, events
Table 2. Person-years and mortality rates for methods of handling immortal time bias by ICD cohort
Methods
ICD No ICD
Adjusted risk differencebN Deaths Person-years Mortalitya N Deaths Person-years Mortalitya
ManteleByar 1,274 452 2,639 171 4,576 2,093 7,000 299 0.06
Landmark at 60 d 741 252 1,369 184 4,013 1,862 6,960 268 0.08
Landmark at 120 d 810 259 1,432 181 3,631 1,575 6,141 256 0.06
Exclusion 1,274 452 2,149 210 3,952 2,093 6,510 321 0.11
Abbreviation: ICD, implantable cardioverter defibrillator.
a Deaths per 1,000 person-years.
b Adjusted for propensity score in Cox proportional hazards model.
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were unlikely to be related to the therapy. In our example as-
sessing the effectiveness of ICDs, the landmark method pro-
vided not only a valid but also a clinically meaningful
approach to assessing the effectiveness of the therapy owing
to the expected delayed effect. Researchers should assess
whether the landmark method could provide meaningful es-
timates for their study question and choose an appropriate
landmark time based on the natural time of clinical signifi-
cance (i.e., the end of induction therapy in patients with can-
cer) before the data analysis [8] and consider multiple
landmark times in sensitivity analyses.
As expected, the exclusion method yielded the smallest
hazard ratios and approximately 16% bias in favor of treat-
ment. This method estimates the hazard correctly in the
ICD group but overestimates the hazard in the non-ICD
group because the immortal time is excluded from the de-
nominator of the hazard calculation for the non-ICD group.
As a result, the hazard ratio of treatment is always underes-
timated. The magnitude of this bias depends on the propor-
tion of the excluded immortal time. The more excluded
immortal time, the larger the bias, which was shown in
a simulation study [29].
As expected, the time scale affected the results only when
all person-time was accounted for and appropriately classi-
fied using the ManteleByar method. Contrary to our expec-
tation that time on diseasemight be themost appropriate timeTable 3. ICD use and 3-year mortality by combinations of method and time
than 6
Methods Time scale
Inverse
weighted,
ManteleByar Index discharge 0.79 (0
First heart failure hospitalization 0.73 (0
Birth 0.74 (0
Landmark at 60 d Index discharge 0.72 (0
First heart failure hospitalization 0.71 (0
Birth 0.71 (0
Landmark at 120 d Index discharge 0.80 (0
First heart failure hospitalization 0.80 (0
Birth 0.79 (0
Exclusion Index discharge 0.66 (0
First heart failure hospitalization 0.67 (0
Birth 0.67 (0
Abbreviations: ICD, implantable cardioverter defibrillator; CI, confidence
a From Cox proportional hazards models comparing ICD use with non-ICscale in the study, using time on study yielded a larger hazard
ratio (0.83 vs. 0.78) than using first hospitalization or date of
birth. Although disease duration is likely to affect the out-
come, and the timing of device use is likely to be associated
with disease duration, we probably did not capture the true
scale for disease duration using our surrogatemeasure,which
was the time from the first hospitalization.
Our study has limitations. First, the true effect of ICD
therapy in the study population is unknown. As a conse-
quence, we relied on trial data and existing evidence to de-
rive an expected effect in this population and estimated the
relative amount of bias compared with the reference
ManteleByar method. Currently, an extensive simulation
study is being conducted to determine the magnitude of
bias introduced as the risk for exposure varies over time.
Second, we did not adjust for registry variables or have
access to outpatient and pharmacy data for estimating the
hd-PS. Therefore, the extent of residual confounding may
be larger, and direct comparison between the hazard ratios
from the major trials and our estimates may be inappropri-
ate. Third, the choice of the landmark time cannot be
generalized and should be based on the natural time of clin-
ical significance. Exclusion of patients who died before
the landmark time may affect statistical efficiency and
precision.
Immortal time bias is well recognized and described in
the epidemiology and pharmacoepidemiology literaturescale after restriction to patients with inverse probability weights less
probability
HR (95% CI)a
Stratified, HR
(95% CI)
Propensity score as
covariate, HR (95% CI)
.68e0.92) 0.83 (0.74e0.94) 0.84 (0.75e0.95)
.63e0.85) 0.78 (0.69e0.88) 0.78 (0.69e0.89)
.63e0.86) 0.78 (0.69e0.88) 0.79 (0.70e0.89)
.61e0.84) 0.79 (0.69e0.90) 0.78 (0.68e0.89)
.60e0.84) 0.78 (0.68e0.90) 0.77 (0.67e0.88)
.60e0.83) 0.79 (0.68e0.90) 0.77 (0.67e0.88)
.68e0.94) 0.83 (0.72e0.95) 0.82 (0.72e0.95)
.68e0.94) 0.82 (0.72e0.95) 0.82 (0.71e0.94)
.67e0.93) 0.83 (0.73e0.96) 0.82 (0.71e0.94)
.58e0.77) 0.70 (0.62e0.78) 0.71 (0.63e0.80)
.57e0.78) 0.71 (0.63e0.80) 0.72 (0.64e0.82)
.58e0.78) 0.70 (0.62e0.79) 0.72 (0.64e0.82)
interval; HR, hazard ratio.
D use.
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and underrecognized in observational studies of the com-
parative effectiveness of medical devices. Researchers
should be aware of the immortal time bias caused by mis-
classifying or omitting immortal time and should choose
appropriate study designs and statistical methods to allocate
person-time to appropriate exposure categories, such as the
ManteleByar method. The landmark method is likely to re-
sult in valid results if the method can provide valid and
meaningful estimates for a specific study question and an
appropriate landmark time is selected.
Appendix
Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.jclinepi.2013.01.014.
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